Dublin, April 01, 2020 (GLOBE NEWSWIRE) -- The "Graft-Versus-Host Disease: Epidemiology Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.

GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation.

The publisher epidemiologists utilized historical HSCT data available through country-wide registry reports in the 5GM to the best extent possible to arrive at a meaningful in-depth analysis and forecast for GvHD. In this analysis, The publisher epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGvHD and cGvHD incident cases. Further, The publisher epidemiologists used country-specific estimates using valid diagnostic criteria to present aGvHD and cGvHD prevalent, grades and mortality cases.

The following data describes epidemiology of GvHD cases. In 2018, the 5GM had 8,794 diagnosed incident cases of GvHD (aGvHD and cGvHD). This is expected to increase to 13,673 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 5.55%. This increase is partly attributed to the moderately rising trend in incidence in transplantation in the 5GM. In the 5GM, the diagnosed incident cases of aGvHD will increase from 4,650 cases in 2018 to 7,212 cases in 2028, at an Annual Growth Rate (AGR) of 5.51% per year, and the diagnosed incident cases of cGvHD will increase from 4,144 cases in 2018 to 6,461 cases in 2028, at an AGR of 5.59% per year.

Scope

Reasons to Buy

Key Topics Covered:

1 Table of Contents1.1 List of Tables1.2 List of Figures

2 Graft-Versus-Host Disease: Executive Summary2.1 Related Reports2.2 Upcoming Reports

3 Epidemiology3.1 Disease Background3.2 Risk Factors and Comorbidities3.3 Global and Historical Trends3.3.1 Australia3.3.2 China3.3.3 India3.3.4 Japan3.3.5 South Korea3.4 Forecast Methodology3.4.1 Sources Used3.4.2 Sources Not Used3.4.3 Forecast Assumptions and Methods3.5 Epidemiological Forecast for GvHD (2018-2028)3.5.1 Incident Cases of First Allogeneic HSCT3.5.2 Incident Cases of aGvHD in First Allogeneic HSCT3.5.3 Incident Cases of cGvHD in First Allogeneic HSCT3.5.4 Age-Specific Incident Cases of aGvHD and cGvHD3.5.5 Diagnosed Incident Cases of aGvHD by Grade3.5.6 Diagnosed Incident Cases of cGvHD by Severity3.5.7 100-Day Mortality in Diagnosed Incident Cases of aGvHD3.5.8 One-Year Mortality in Diagnosed Incident Cases of cGvHD3.5.9 Three-Year Diagnosed Prevalent Cases of aGvHD3.5.10 Three-Year Diagnosed Prevalent Cases of cGvHD3.6 Discussion3.6.1 Epidemiological Forecast Insight3.6.2 Limitations of Analysis3.6.3 Strengths of Analysis

4 Appendix4.1 Bibliography4.2 About the Authors4.2.1 Epidemiologist4.2.2 Reviewers4.2.3 Global Director of Therapy Analysis and Epidemiology4.2.4 Global Head and EVP of Healthcare Operations and Strategy4.3 About the publisher4.4 Contact Information4.5 Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/8yhcjq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Visit link:
Insights into the Asia-Pacific Graft-Versus-Host Disease Industry to 2028 - Develop Business Strategies by Understanding the Trends Shaping and...

Skin Stem Cells Comments Off on Insights into the Asia-Pacific Graft-Versus-Host Disease Industry to 2028 – Develop Business Strategies by Understanding the Trends Shaping and… | April 1st, 2020

Researchers at the Institute of Oral Biology of the University of Zurich have released 2 studies that examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.

Their findings demonstrate that different stem cell populations are innervated in distinct ways and that innervation may be crucial for proper tissue regeneration, according to the study. They also demonstrate that cancer steam cells likewise establish contacts with nerves.

Stem cells can generate a variety of specific tissues that are increasingly being used for clinical application, such as the replacement of bone or cartilage, but are present in cancerous tissues and are involved in cancer progression and metastasis. Nerves are therefore fundamental for regulating the physiological and regenerative processes involving stem cells.

Using organ-on-a-chip technology, which relies on small 3-dimensional devices mimicking the basic function of human organs and tissues, the researchers demonstrated that both types of stem cells promoted neuronal growth. The dental pulp stem cells, however, yielded better results compared with bone marrow stem cells. They induced more elongated neurons, formed dense neuronal networks, and established close contacts with nerves.

Dental stem cells produce specific molecules that are fundamental for the growth and attraction of neurons. Therefore, stem cells are abundantly innervated, according to the study authors. The formation of such extended networks and the establishment of numerous contacts suggest that dental stem cells create functional connections with nerves of the face. Therefore, these cells could represent an attractive choice for the regeneration of functional, properly innervated facial tissue.

In the second study, the researchers examined the interaction between nerves and cancer stem cells found in ameloblastoma, an aggressive tumor of the mouth. They first demonstrated that ameloblastomas have stem cell properties and are innervated by facial neurons. When ameloblastoma cells were isolated and placed in the organ-on-a-chip devices, they retained not only their stem cell properties, but also attracted nerves and established contact with them.

Nerves appear to be fundamental for the survival and function of cancer stem cells. These results create new possibilities for cancer treatment using drugs that modify the communication between neurons and cancer stem cells. The researchers hope this opens unforeseen paths toward effective therapies against cancer.

The combination of advanced molecular and imaging tools and organ-on-a-chip technology offers an opportunity to reveal the hidden functions of neurons and their interactions with various stem cell types, in both healthy and pathological conditions.

Reference

See original here:
Stem Cells, Nerves Found to Interact in Cancer Progression - Pharmacy Times

Bone Marrow Stem Cells Comments Off on Stem Cells, Nerves Found to Interact in Cancer Progression – Pharmacy Times | April 1st, 2020

Dr. Jim Surrell, Journal columnist

The overall function of our human immune system is to prevent or limit infection. The primary job of our immune system is to distinguish between our normal, healthy cells and possible other dangerous cells, such as viruses and bacteria that may come into our blood stream. Our immune system is always on duty to look for and recognize these possible infectious viruses and bacteria.

The immune system looks closely at these potentially infectious cells to do all it can to prevent us from getting an infection.

Know that we rely on our immune system every day to help us fight off infections and keep us healthy. Our immune system contains numerous cell types that either circulate throughout the body or reside in our particular body tissues. Each cell type plays a unique role, with different ways of performing their function to fight off infections. Further, our great medical and scientific researchers continuously work to optimize our immune responses to confront specific potential infectious issues, such as is being done at this time with regard to the coronavirus (COVID-19).

Let us now take a look at the many components of our human immune system and how our body works to fight off infections. All of our numerous immune cells come from basic immune cells in our bone marrow and develop into mature cells through a series of changes that can occur in different parts of the body. Following is a brief look at our various body components that make up our immune system.

Skin: Our skin is usually the first line of defense against infectious organisms. Skin cells produce and secrete important antimicrobial proteins, and immune cells can be found in specific layers of our skin.

Bone marrow: Our bone marrow contains stem cells that can develop into a variety of cell types. These stem cells in our bone marrow develop our many various types of immune cells that are very important first-line responders to infection. These stem cells create our essential infection-fighting cells, called B cells and T cells. These B cells and T cells are responsible for mounting a response to specific microbes that may cause infections. We also have natural niller (NK) immune cells that also provide defenses to fight off infections. These immune system B cells, T cells, and NK cells are also called lymphocytes.

Bloodstream: Immune cells constantly circulate throughout the bloodstream, patrolling for problems. When blood tests are used to monitor white blood cells, another term for immune cells, a snapshot of the immune system is taken. If our white blood cells are too few, or overabundant in the bloodstream, this may reflect a problem that should be addressed by a professional health care provider.

Thymus Gland: Immune system T cells mature in our small thymus gland, located in the upper chest.

Lymphatic system: The lymphatic system is a network of vessels and tissues composed of lymph, an extracellular fluid, and our lymph nodes. The lymphatic system is the essential part of our immune system that provides communication between our various body tissues and our bloodstream. Immune cells are carried through the lymphatic system and converge in lymph nodes. Lymph nodes are a communication hub where immune cells sample information brought in from the body. Thus, doctors may check patients for swollen lymph nodes, which may indicate an active immune response.

Spleen: The spleen is an organ located behind the stomach. Immune cells are found in the spleen and if there are any blood-borne infectious organisms, these immune cells activate and respond accordingly.

Lastly, be aware that our human immune system regenerates and repairs itself every night when we sleep. Studies show that people who dont get quality sleep or enough sleep are more likely to get sick after being exposed to an infectious virus or bacteria. Lack of sleep can also affect how fast you recover if you do get sick. To keep you and your immune system healthy, get the recommended seven to eight hours of sleep each and every night. And yes, these are Doctors Orders!

EDITORS NOTE: Dr. Jim Surrell is the author of The ABCs For Success In All We Do and the SOS (Stop Only Sugar) Diet books. Requests for health topics for this column are encouraged. Contact Dr. Surrell by email at sosdietdoc@gmail.com.

At the time I am writing to you, scientists are hunched over test tubes and Petri dishes in a desperate race ...

MARQUETTE The 2020 Seasonal Slip Agreements were mailed to the 2019 seasonal slip holders Monday. Payments will ...

View post:
Talk with the Doc | News, Sports, Jobs - Marquette Mining Journal

Bone Marrow Stem Cells Comments Off on Talk with the Doc | News, Sports, Jobs – Marquette Mining Journal | April 1st, 2020

VIVA! Communications

Australians living with an incurable blood cancer set to receive new reimbursed treatment option

Australians living with the incurable blood cancer, multiple myeloma1 are set to gain access to a new treatment option, with the listing of REVLIMID(lenalidomide) for maintenance treatment on the Pharmaceutical Benefits Scheme (PBS) from Wednesday April 1, 2020.2

REVLIMID(lenalidomide) represents Australias first and only maintenance treatment specifically indicated and reimbursed for those newly diagnosed with multiple myeloma (NDMM) who have undergone an autologous stem cell transplant (ASCT). 2, 3

This announcement coincides with an article just published in Medical Journal of Australias MJA Insight, calling for timely access to effective treatments for those living with multiple myeloma.4

According to article author, Professor Miles Prince, Clinical Haematologist and Director of Cancer Immunology and Molecular Oncology (Epworth Healthcare, Melbourne), continuing to broaden access to multiple myeloma treatments is critical to improving patient quality of life.4

Currently, people living with myeloma have a median survival rate of more than seven years which is significant in comparison to the median survival rate of just three years in the early 2000s.4

For survival rates to continue to improve however, patients must receive timely access to the most effective treatments, said Prof. Prince.

The PBS listing of maintenance for multiple myeloma will provide newly diagnosed patients with an additional treatment option for their disease.

Not to be confused with the skin cancer, melanoma, multiple myeloma is an incurable blood cancer that develops from plasma cells, a type of white blood cell found in the bone marrow.5, 6

Representing Australias third most common blood cancer (after lymphoma and leukaemia),7, 8 approximately 18,000 Australians are living with multiple myeloma at any given time,1 only half of whom will survive five years post- diagnosis.9

Myeloma Australia CEO, Steve Roach, today welcomed the availability of a new treatment option for the incurable disease.

The multiple myeloma patient journey involves a pattern of Response, Remission and Relapse, with individuals responding differently to certain treatments due to the complex nature of the devastating disease.

Additional treatment options are required throughout the patient journey, for both the newly diagnosed, and those who have already commenced therapy. Although incurable, we hope that multiple myeloma will one day be treated as a chronic, rather than a terminal disease, Mr Roach said.

The incurable nature of the disease and the likelihood of relapse, may have a psychological impact on patients, who can continue to live in fear even during periods of remission.10, 11

With studies revealing more than half (52%) of those living with multiple myeloma experience symptoms of anxiety or depression,12 improving access to treatment, and extending time spent in remission, may help to improve psychological wellbeing.

Wife and mother-to-two, Maria (53) was diagnosed with multiple myeloma in December 2018 and found her initial diagnosis very overwhelming.

When my husband Danny and I first heard the diagnosis, we were completely overwhelmed. We didnt know what Myeloma was and we didnt know what this meant short or long term. I didnt know if I was going to die in a month, a year or 10 years. How on earth was I going to tell everyone I had cancer, said Maria.

During my journey I blogged about my experience with multiple myeloma and posted to my Facebook daily to keep the calls and fears of my family and friends at bay. I have since accepted that myeloma is now a part of my life. I have no anger or fear and instead just live in the moment and take one day at a time.

Its very exciting to see new treatment options for multiple myeloma being funded by the government, and I hope to keep raising awareness, to ensure the myeloma community continues to receive access to the best treatment options available, Maria said.

About multiple myeloma

Multiple myeloma is a cancer that develops from abnormal plasma cells. A plasma cell is a type of white blood cell found in the bone marrow, that forms part of the immune system and helps to protect against infection.4, 7 The abnormal plasma cells crowd the bone marrow and make it difficult to produce enough normal blood cells.7

Multiple myeloma can be challenging to diagnose due to its wide range of symptoms, including high blood calcium levels, anaemia, fatigue, kidney failure, recurrent infections and bone pain.6

Current treatment for multiple myeloma includes a continuous approach, often comprising initial therapy, consolidation maintenance, and salvage therapy.13 Treatment options for multiple myeloma include chemotherapy, corticosteroids, autologous stem cell transplant (ASCT), immunomodulating drugs (IMiDs) monoclonal antibodies therapy, and proteasome inhibitors.14, 15

About REVLIMID (lenalidomide)

Representing an oral medication approved for the treatment of relapsed myeloma over 10 years ago,16 REVLIMID is an immunomodulating agent (IMiD) that slows the growth of multiple myeloma plasma tumour cells and proteins know to play a key role multiple myeloma, delays the development of new blood vessels, and enhances immune function.3

The most commonly reported side-effects of REVLIMID include diarrhoea, constipation, nausea, vomiting, stomach pain, indigestion, dehydration, dry mouth, mouth ulcer, sore mouth, increase or decrease in weight, increase or decrease in appetite, loss of taste, itchiness, rash, redness of the skin, dry skin, bruising, excessive sweating, dizziness, fainting, headache, shaking or tremors, unusual weakness, night sweats, reduced sense of touch, difficulty sleeping, depression, anxiety, feeling of confusion, back pain, muscle spasms, muscle and/or joint pain, swollen joints, bone pain, muscular weakness, pain in the extremities, feeling tired, falling, swelling of hands, ankles or feet.17

Other possible side effects of REVLIMID include heart palpitations or fast heartbeat, chest pains, dizziness or fainting, shortness of breath, weakness or reduced ability to exercise, bleeding (including nose-bleeds), bruising more than usual, numbness, tingling, blurred vision or difficulty seeing, passing large amounts of urine, excessive thirst, and having a dry mouth and skin, abnormal eye movements, convulsions, mood changes, irregular heart rhythms or tender swollen lymph nodes. 17

All patients receiving REVLIMID must be registered on, and abide by the requirements of, i-access risk management program to avoid exposure to unborn babies, due to the potential for birth defects. It is important to note that a small number of patients with multiple myeloma may develop additional types of cancer, regardless of their type of therapy. At this stage, it cannot be excluded that this risk may be slightly increased with REVLIMID maintenance treatment.17

Disclosure

Celgene supports disclosure and transparency on interactions between the healthcare industry and healthcare professionals to ensure public trust and confidence. No expert spokespeople have been offered compensation for their involvement in this media campaign. All expert spokespeople have been briefed on the approved use of these products and their obligations with regard to promotion to the general public. Prof Miles Prince and Myeloma Australia have received funding from Celgene for projects unrelated to this announcement. All opinions expressed are their own.

About Celgene

Celgene, a Bristol-Myers Squibb Company, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases, through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

/Public Release.

See the article here:
Australians living with an incurable blood cancer set to receive new reimbursed treatment option - Mirage News

Bone Marrow Stem Cells Comments Off on Australians living with an incurable blood cancer set to receive new reimbursed treatment option – Mirage News | April 1st, 2020

VANCOUVER, Washington, March 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that an additional three critically ill COVID-19 patients have been treated with leronlimab. These additional patients increase the total to 10 patients receiving leronlimab treatment under an Emergency Investigational New Drug (EIND) granted by the U.S. Food and Drug Administration (FDA).

The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19). Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the cytokine storm that leads to morbidity and mortality in these patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved. The results of the three additional patients are expected this week.

Jacob Lalezari, M.D., Interim Chief Medical Officer of CytoDyn, commented, The preliminary results observed in patients who were severely ill with COVID-19 and treated with leronlimab are encouraging. Although the data set is still small, we saw fairly rapid and positive laboratory responses in all 4 patients treated, and in three of the 4 patients these laboratory results were associated with a favorable clinical outcome. We eagerly await the results of additional patients treated under the FDAs emergency IND program, as well as the results of several randomized clinical trials about to start.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, added, We remain encouraged and hopeful that leronlimab will help patients from this devastating and relentless disease. We will aggressively pursue treatment for COVID-19 patients, and to explore leronlimabs role in helping to alleviate the impending burden of supply chain and institutional capacity issues.

About Coronavirus Disease 2019SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEO RedChip Companies Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com

Follow this link:
Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients - Associated Press

Bone Marrow Stem Cells Comments Off on Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients – Associated Press | March 31st, 2020

Dailymail.co.uk

Adam Castillejo (pictured), 40, was known only as the London Patient when doctors revealed his success story last March after a stem cell transplant to treat his cancer.

The second person to be cured of HIV has revealed how he was more fearful of dying from cancer than Aids and considered ending his life at Dignitas.Adam Castillejo, 40, was known only as the London Patient when doctors revealed his success story last March after a stem cell transplant to treat his cancer.He remained anonymous until he decided he wanted to be seen as an ambassador of hope after struggling with his health for almost two decades.Mr Castillejo, who was born in Venezuela and moved to London in 2002, was diagnosed with blood cancer in 2012, having already lived with HIV since 2003.His last hope of cancer survival was a bone marrow transplant from a donor with HIV-resistant genes that could wipe out his cancer and virus in one fell swoop.But in a powerful interview with The Sunday Times,Mr Castillejo admitted that he was more fearful of dying from stage 4 Hodgkins lymphoma than Aids.Calling the second diagnosis another death sentence, the sou-chef revealed that he panicked because cancer can kill you faster than HIV.Adam Castillejo, 40, was known only as the London Patient when doctors revealed his success story last March after a stem cell transplant to treat his cancerMr Castillejo embarked upon a gruelling treatment regime that left him physically emaciated and pushed the Venezuelan to the mental edge.Both illnesses became one because you had to deal with the anti-retroviral medications not interfering with thechemotherapy regime and vice versa, he said.By the end of 2014, he said that he had given up on battling the two illnesses, and had made up his mind to end it all at Dignitas in Switzerland.Around this time,Mr Castillejo disappeared, and was found four days later outside London psychologically broken. He does not remember this period.Doctors gave him six months to live, before a switch flicked.At that time I accepted straight away, because what choice have I got? I would rather die fighting, he explained.Within days, he met with Dr Ian Gabriel at the Chelsea and Westminster Hospital, who advised that he could attempt a bone marrow transplant.The procedure in May 2016 meantMr Castillejo was cleared of both cancer and HIV.But he lost five stone and took 60 pills a day, revealing: I told my doctors there werent enough hours in the day to take all the medication I needed.Mr Castillejo, who was born in Venezuela and moved to London in 2002, was diagnosed with blood cancer in 2012, having already lived with HIV since 2003An American man treated in Germany 12 years ago called Timothy Ray Brown (pictured) the so-called Berlin Patient also survived the transplantHe also developed mouth ulcers which inhibited his ability to eat, and his anti-retroviral medication had to be crushed and washed down.Mr Castillejo also claimed that he felt victimised and guilty when he told people that he was suffering from HIV, saying: This is a punishment for you.The Venezuelan chef is the second person to have survived the life-threatening technique and come out the other side HIV-free.An American man treated in Germany 12 years ago called Timothy Ray Brown the so-called Berlin Patient also survived the transplant.He was put into an induced coma for six months, however.Experts have hailed the treatment as a milestone in the fight against HIV, but are urging caution when calling it a cure so early on.In the context of HIV infection, the term cure means there are no virus-carrying cells left.Anti-retroviral therapy is very effective at reducing the viral load in the blood of infected individuals so that it cannot be transmitted to others.Unfortunately, the Berlin and London Patients cases do not change the reality much for 37 million HIV patients.The treatment is unlikely to have potential on a wider scale because both Mr Castillejo and Mr Ray Brown were given stem cells to treat cancer, not HIV.Stem cell and bone marrow transplants are life-threatening operations with huge risks. Patients can suffer a fatal reaction if substitute immune cells dont take.In his private life, Mr Castillejo likes to walk the streets of Shoreditch and travel.Kat Smithson, director of policy at National AIDS Trust, said: We applaud the London Patient Adam Castillejo for sharing his unique experience of having his HIV cured following a bone-marrow transplant to treat cancer. Mr Castillejo has been through a long and extremely challenging journey with his health, within which HIV is just one part.His decision to speak about his experience without anonymity can only enrich our understanding of his experience on a human level, and we thank him for this.Theres still a great deal of stigma around HIV which can make it harder for people to access the services and support they need and for people to talk openly about HIV.His story helps raise much-needed awareness of HIV, but broader than that its a story about incredible resilience, determination and hope.How a stem cell transplant cured the Berlin and London Patients and how it can go badly wrongUsually, HIV patients expect to stay on daily pills for life to suppress the virus. When drugs are stopped, the virus roars back, usually in two to three weeksThe vast majority of humans carry the gene CCR5.In many ways, it is incredibly unhelpful. It affects our odds of surviving and recovering from a stroke, according to recent research.And it is the main access point for HIV to overtake our immune systems.But some people carry a mutations that prevents CCR5 from expressing itself, effectively blocking or eliminating the gene.Those few people in the world are called elite controllers by HIV experts. They are naturally resistant to HIV.If the virus ever entered their body, they would naturally control the virus as if they were taking the virus-suppressing drugs that HIV patients require.Both the Berlin patient and the London patient received stem cells donated from people with that crucial mutation.WHY HAS IT NEVER WORKED BEFORE?There are many reasons this hasnt worked, Dr Janet Siliciano, at the Johns Hopkins University School of Medicine, told DailyMail.com.1. FINDING DONORSIts incredibly difficult to find HLA-matched bone marrow [i.e. someone with the same proteins in their blood as you], Dr Siliciano said.Its even more difficult to find the CCR5 mutation.2. INEFFECTIVE TRANSPLANT LEADS TO CANCER RELAPSESecond, there is a risk that the bone marrow wont take.Sometimes you dont become fully chimeric, meaning you still have a lot of your own cells.This means they will not defeat the cancer if it returns again.3. THE OLD IMMUNE SYSTEM ATTACKS THE NEW ONEThe other most common reason this approach has failed is graft-versus-host disease: whenthe patients immune system tries to attack the incoming, replacement immune system, causing a fatal reaction in most.4. UNKNOWN QUANTITIESInterestingly, both the Berlin patient and the London patient experienced complications that are normally lethal in most other cases.And experts believe that those complications helped their cases.Timothy Ray Brown, the Berlin patient, had both his cancer returned and he developed graft-versus-host disease, putting him in a coma and requiring a second bone marrow transplant.The London patient had one: he suffered graft-versus-host disease.Against the odds, they both survived, HIV-free.Some believe that, ironically, graft-versus-host disease might have helped both of them to further obliterate their HIV.But there is no way to control or replicate that safely.

Original post:
Adam Castillejo 'feared dying of cancer more than Aids and considered ending it all at Dignitas' Daily Mail - westofthepond.com

Bone Marrow Stem Cells Comments Off on Adam Castillejo ‘feared dying of cancer more than Aids and considered ending it all at Dignitas’ Daily Mail – westofthepond.com | March 31st, 2020

Researchers at Stanford University report that they can rejuvenate human cells by reprogramming them back to a youthful state. They hope that the technique will help in the treatment of diseases, such as osteoarthritis and muscle wasting, that are caused by the aging of tissue cells.

A major cause of aging is thought to be the errors that accumulate in the epigenome, the system of proteins that packages the DNA and controls access to its genes. The Stanford team, led by Tapash Jay Sarkar, Dr. Thomas A. Rando and Vittorio Sebastiano, say their method, designed to reverse these errors and walk back the cells to their youthful state, does indeed restore the cells vigor and eliminate signs of aging.

In their report, published on Tuesday in Nature Communications, they described their technique as a significant step toward the goal of reversing cellular aging and could produce therapies for aging and aging-related diseases.

Leonard P. Guarente, an expert on aging at M.I.T., said the method was one of the most promising areas of aging research but that it would take a long time to develop drugs based on RNA, the required chemical.

The Stanford approach utilizes powerful agents known as Yamanaka factors, which reprogram a cells epigenome to its time zero, or embryonic state.

Embryonic cells, derived from the fertilized egg, can develop into any of the specialized cell types of the body. Their fate, whether to become a skin or eye or liver cell, is determined by chemical groups, or marks, that are tagged on to their epigenome.

In each type of cell, these marks make accessible only the genes that the cell type needs, while locking down all other genes in the DNAs. The pattern of marks thus establishes each cells identity.

As the cell ages, it accumulates errors in the marking system, which degrade the cells efficiency at switching on and off the genes needed for its operations.

In 2006 Dr. Shinya Yamanaka, a stem-cell researcher at Kyoto University, amazed biologists by showing that a cells fate could be reversed with a set of four transcription factors agents that activate genes that he had identified. A cell dosed with the Yamanaka factors erases the marks on the epigenome, so the cell loses its identity and reverts to the embryonic state. Erroneous marks gathered during aging are also lost in the process, restoring the cell to its state of youth. Dr. Yamanaka shared the 2012 Nobel Prize in medicine for the work.

But the Yamanaka factors are no simple panacea. Applied to whole mice, the factors made cells lose their functions and primed them for rapid growth, usually cancerous; the mice all died.

In 2016, Juan Carlos Izpisua Belmonte, of the Salk Institute for Biological Studies in San Diego, found that the two effects of the Yamanaka factors erasing cell identity and reversing aging could be separated, with a lower dose securing just age reversal. But he achieved this by genetically engineering mice, a technique not usable in people.

In their paper on Tuesday, the Stanford team described a feasible way to deliver Yamanaka factors to cells taken from patients, by dosing cells kept in cultures with small amounts of the factors.

If dosed for a short enough time, the team reported, the cells retained their identity but returned to a youthful state, as judged by several measures of cell vigor.

Dr. Sebastiano said the Yamanaka factors appeared to operate in two stages, as if they were raising the epigenomes energy to one level, at which the marks of aging were lost, and then to a higher level at which cell identity was erased.

The Stanford team extracted aged cartilage cells from patients with osteoarthritis and found that after a low dosage of Yamanaka factors the cells no longer secreted the inflammatory factors that provoke the disease. The team also found that human muscle stem cells, which are impaired in a muscle-wasting disease, could be restored to youth. Members of the Stanford team have formed a company, Turn Biotechnologies, to develop therapies for osteoarthritis and other diseases.

The study is definitively a step forward in the goal of reversing cellular aging, Dr. Izpisua Belmonte said.

View post:
Turning Back the Clock on Aging Cells - The New York Times

Skin Stem Cells Comments Off on Turning Back the Clock on Aging Cells – The New York Times | March 31st, 2020

Guy Rouleau, shown at middle in 2010, is director of the Montreal Neurological Institute and Hospital and one of the recipients of this year's Gairdner Awards. The others are Mina Bissell, top left; Salim and Quarraisha Abdool Karim, middle left; Elaine Fuchs, bottom left; Rolf Kemier, top right; Masatoshi Takeichi, middle right; and Roeland Nusse, bottom right.

John Morstad/The Globe and Mail, handouts

A diverse group of eight scientists whose work has offered insight into how cells interact with each other and their environment, the genetic underpinnings of neurological disease and the transmission of the virus that causes AIDS, have been named this years winners of the Gairdner Awards the countrys most prestigious biomedical research prizes.

Coming in the midst of the COVID-19 pandemic, this years set of awards highlights the importance of basic science to understanding the fundamental processes of life and how those processes relate to human health around the world.

When you build up a scientific environment and a scientific community, you have people who are prepared to do whatever it takes [to address a global health crisis], said Janet Rossant, president and scientific director of the Toronto-based Gairdner Foundation, which announced the award winners on Tuesday. You never know whats going to give you insight into disease, Dr. Rossant said.

Story continues below advertisement

Guy Rouleau works in a Montreal lab in 2017.

Paul Chiasson/The Canadian Press

Among the winners is Guy Rouleau, director of the Montreal Neurological Institute and Hospital, who is this years recipient of the Gairdner Wightman Award, which recognizes scientific leadership in Canada.

In addition to his work linking various rare genes that occur in the French Canadian population to disorders such as ALS (Amyotrophic Lateral Sclerosis), Dr. Rouleau is known for his efforts to make scientific research more accessible.

Starting in 2016, he placed his institute at the forefront of the open science movement by allowing the free flow of data, tools and research results without restrictions related to who will profit from the knowledge.

Reached at his home in Montreal, Dr. Rouleau said the initiative was spurred by a lack of new development in neurological disease, where few treatment options are available for those dealing with brain disorders including Alzheimers disease. We thought that by sharing openly and by breaking down barriers, this would accelerate things, Dr. Rouleau said.

A human T-cell, in blue, comes under attack by HIV, in yellow, the virus that causes AIDS.

Seth Pincus, Elizabeth Fischer, Austin Athman/National Institute of Allergy and Infectious Diseases/NIH via AP

The husband and wife team of Quarraisha and Salim Abdool Karim at the Centre for the AIDS Programme of Research in South Africa were named the joint winners of the John Dirks Gairdner Globe Health award for their work tackling HIV in Africa.

In 1990, the pair described the transmission of the virus that causes AIDS through the African population, which frequently involves the infection of teenage girls by older men. Their work laid the foundations for successful HIV prevention programs focused on women and womens health.

Previous winners of the global health award include Anthony Fauci of the National Institutes of Health in Bethesda, Md., who has lately become a prominent figure for helping to steer the U.S. response to COVID-19 and for repeatedly clarifying or correcting misleading statements by U.S. President Donald Trump.

Story continues below advertisement

Past Gairdner recipient Dr. Anthony Fauci walks past U.S. President Donald Trump at a March 29 news conference at the White House.

Al Drago/Reuters

The five researchers named as recipients of this years Canada Gairdner International Award a prize that often portends a future Nobel win have all done groundbreaking work related to some aspect of the field known as cell signalling.

They include:

In previous years, Gairdner award winners have travelled across Canada giving lectures and meeting with students ahead of a fall symposium and award ceremony in Toronto.

Dr. Rossant said the Foundation is still assessing how this years activities will proceed in light of COVID-19.

Sign up for the Coronavirus Update newsletter to read the days essential coronavirus news, features and explainers written by Globe reporters.

Excerpt from:
In a coronavirus crisis, Gairdner Awards honour eight explorers of how cells, genes and viruses work - The Globe and Mail

Skin Stem Cells Comments Off on In a coronavirus crisis, Gairdner Awards honour eight explorers of how cells, genes and viruses work – The Globe and Mail | March 31st, 2020

Pablo Saldivia Salgado / EyeEm/Getty Images

They say its the little things that matter, and when it comes to skincare, we have to agree. Few things feel better than the sensation of a freshly scrubbed face. Trouble is, few of us know how to actually get that feeling consistently. Sure, you may know that the key to a clear, healthy complexion is exfoliation (i.e., shedding the uppermost layer of dead skin cells). But what you use to exfoliate makes a big difference in whether you come away with a radiant glow or a mask of raw, irritated epidermis.

There are a few types of products that will do the job, but exfoliating face scrubs are often the most preferred. Known as physical exfoliants (as opposed to chemical exfoliants), these facial scrubs use tiny abrasive grains that act like sandpaper on your face, using friction to buff dead skin cells away. Physical exfoliants can be made from natural ingredients like apricot kernels, sugar, even coffee, or they can be synthetic beads that dissolve as you use them. Some guys love this type of exfoliant because you can really feel it working. However, it can be pretty harsh on some sensitive skin, leaving your face red and irritated, which leads to dry skin, increased oil production, or even scarring (and not in a sexy Jason Momoa kind of way).

That doesnt mean you shouldnt use an exfoliating scrub. It just means you have to do your homework or, if youd rather, have us do it for you. Weve put together a list of our favorite exfoliating face scrubs that contain quality ingredients for buffing away dead skin, and soothing the new skin underneath so that it stays happy, hydrated, and balanced. Gently (and we mean gently) massage these facial exfoliator scrubs into your forehead, chin, and cheeks, splash with cold water, pat dry, and finish with a kiss of moisturizer, and youll feel your face glowing all day long.

Finely ground apricot seed sloughs away yesterdays skin, with a little extra help from papaya extract enzymes, while chamomile, aloe, and sea kelp nourish and hydrate whats underneath.

For nights when youre ready to do some deep cleaning, pick this ultra-pure exfoliating mask. Activated charcoal and bentonite clay absorb impurities from your skin while the mask remains on your face. Scrubbing it off leaves your face not only clear, but also unbelievably soft, thanks to the addition of willow bark, rosemary extract, and sulfur mud.

Ground walnut shells and bamboo stem polish your skin, while jojoba esters and tropical fruit extracts break down pore-clogging oils, and special hydrating sugar technology blend rebuilds your skins moisture barrier before you rinse clean.

This super-concentrated, double-action exfoliating face scrub doesnt play around. Tiny jojoba beads offer a physical exfoliation that is boosted with the chemical exfoliating power of glycolic and salicylic acid. Five minutes with this scrub, and youll look and feel like a new man.

Sometimes, the simplest solutions are the best. This easy-to-find face scrub boasts natural ingredients such as aloe, hemp, and other nutrient-rich botanicals that ensure your newly scrubbed skin doesnt get dry or irritated.

Follow this link:
Give Your Face a Spring Refresh With These Exfoliating Face Scrubs - The Manual

Skin Stem Cells Comments Off on Give Your Face a Spring Refresh With These Exfoliating Face Scrubs – The Manual | March 31st, 2020

A team of University of California, Irvine researchers have published the first comprehensive overview of the major changes that occur in mammalian skin cells as they prepare to heal wounds. Results from the study provide a blueprint for future investigation into pathological conditions associated with poor wound healing, such as in diabetic patients.

"This study is the first comprehensive dissection of the major changes in cellular heterogeneity from a normal state to wound healing in skin," said Xing Dai, PhD, a professor of biological chemistry and dermatology in the UCI School of Medicine, and senior author. "This work also showcases the collaborative efforts between biologists, mathematician and physicists at UCI, with support from the National Institute of Arthritis & Musculoskeletal & Skin Diseases-funded UCI Skin Biology Resource-based Center and the NSF-Simons Center for Multiscale Cell Fate Research.

The study, titled, "Defining epidermal basal cell states during skin homeostasis and wound healing using single-cell transcriptomics," was published this week inCell Reports.

"Our research uncovered at least four distinct transcriptional states in the epidermal basal layer as part of a 'hierarchical-lineage' model of the epidermal homeostasis, or stable state of the skin, clarifying a long-term debate in the skin stem cell field," said Dai.

Using single-cell RNA sequencing coupled with RNAScope and fluorescence lifetime imaging, the team identified three non-proliferative and one proliferative basal cell state in homeostatic skin that differ in metabolic preference and become spatially partitioned during wound re-epithelialization, which is the process by which the skin and mucous membranes replace superficial epithelial cells damaged or lost in a wound.

Epithelial tissue maintenance is driven by resident stem cells, the proliferation and differentiation dynamics of which need to be tailored to the tissue's homeostatic and regenerative needs. However, our understanding of tissue-specific cellular dynamics in vivo at single-cell and tissue scales is often very limited.

"Our study lays a foundation for future investigation into the adult epidermis, specifically how the skin is maintained and how it can robustly regenerate itself upon injury," said Dai.

Link:
Study reveals how skin cells prepare to heal wounds - Jill Lopez

Skin Stem Cells Comments Off on Study reveals how skin cells prepare to heal wounds – Jill Lopez | March 30th, 2020

It is a universally acknowledged fact that the majority of women refuse to age, the moment they reach the age of 40. The desire to turn back the clock is something that gets automatically etched on their minds, after hitting middle age. Making a wise choice from the wide range of anti-ageing solutions available for women can be a highly baffling affair, but understanding the skins needs is equally crucial.

So what exactly is ageing, that every person, especially women dread? It can be regarded as a complex process resulting in accrual changes in a persons body over. a period of time. Ageing occurs in fractions, because the stem cells which have the ability to renew themselves grow old as DNA gets damaged and changes occur in the overall physiology. As time passes by and people age, the majority of the cells present in their bodies get replaced and the ability of the body to produce more new cells gradually declines, Thus, anti-ageing retards the degeneration process of the body.

Post an anti-ageing fat stem cell treatment the skin shows prominent signs of turning softer while the body notices a remarkable surge of energy, resulting in improved sleeping and breathing patterns, controlled sugar levels, rebalanced hormones, increased metabolism, average weight loss and fading age spots. This all seems possible owing to the insertion of 30-50 million supercharged active stem cells.

Ageing is indeed complex, as its causes have not yet been completely understood. A big part of ageing occurs when the body is being attacked by inflammation and oxidative stress. Even though it is said that ageing is a natural process which is unavoidable, there is still scope to maintain health and stay young for both preventing age-related diseases and to enjoy the benefits of youth.

The desire to be younger is not exactly a new idea. The concept of anti-ageing has kept humankind occupied since ages, with the idea about staying healthy and fit with age and improving the quality of life. So with the rising evidence about the association of ageing diseases with adult stem cell exhaustion, it will not be surprising to witness an elevation of interest towards restoring the adult stem cell function to improve these conditions and to turn back the clock!

See the article here:
Reversing The Ageing Process With Stem Cell Therapy - Version Weekly

Skin Stem Cells Comments Off on Reversing The Ageing Process With Stem Cell Therapy – Version Weekly | March 30th, 2020

Gerlinde R. Van de Walle, DVM, Ph.D., co-lead for the study.

DURHAM, N.C. (PRWEB) March 26, 2020

Researchers have potentially made a breakthrough in the war on antibiotic-resistant superbugs including MRSA, which kills an estimated 20,000 people in the United States alone each year with a new discovery whose details are published today in STEM CELLS Translational Medicine. The study, by researchers at The Baker Institute for Animal Health, at Cornells College of Veterinary Medicine, demonstrates for the first time that mesenchymal stromal cells (MSCs) are an effective weapon against bacteria in biofilm.

Biofilms are thin, slimy films made up of bacteria that can attach to skin wounds, teeth and other surfaces, creating the opportunity for infections to flourish. These highly structured cellular communities offer bacteria shelter from harmful factors, helping them resist antibiotics, mutate rapidly and evade the immune system.

MSCs help kill the bacteria through the secretion of enzymes, called proteases, that break the peptide bonds of proteins and cause biofilm to destabilize. This in turn increases the effectiveness of antibiotics that previously werent working, as the bacteria are no longer being protected by the biofilm, explained Gerlinde R. Van de Walle, DVM, Ph.D., who led the study along with Charlotte Marx, DVM, Ph.D.

Other recent studies, including one by the Cornell team, have shown that MSCs can inhibit the growth of bacteria associated with chronic infections by secreting antimicrobial peptides. But these studies were conducted primarily on planktonic bacteria, which are individually floating bacteria cells. Thus, information on the effects on biofilms was largely lacking, Dr. Marx said.

The current study explores how MSC secretome, delivered as conditioned medium, performs against various wound-related bacterial pathogens. It also looks at the mechanisms that affect bacterial biofilms. The experiments were performed in vitro, using equine MSC. We use equine MSC in our work since the horse represents a physiologically relevant model for human wound healing and offers a readily translatable model for MSC therapies in humans, Dr. Van de Walle explained.

The researchers began by showing that equine MSC secretome inhibits the growth of four types of planktonic bacteria that commonly colonize skin wounds. Encouraged by the results, they next sought to determine the effect of the MSC secretome on these same bacterial strains in biofilms, which is the predominant way bacteria invade wounds. They looked at how the MSCs affected biofilm formation, then repeated the experiments on biofilms that were already established. Finally, they turned their attention to the bacteria strain responsible for MRSA.

Dr. Marx reported the results. Our salient findings, she said, were that factors secreted by equine MSC impaired both planktonic and biofilms including MRSA as well as disrupted mature biofilms generated by these bacteria. Importantly, we found that these effects resulted from a protease-dependent mechanism.

Dr. Van de Walle added, We also found that MSC-secreted factors allowed previously ineffective antibiotic treatments to become more effective at reducing bacterial survival. In light of the rise of antibiotic-resistant bacterial strains as an increasing global health threat, our findings provide the rationale for using the MSC secretome as a complementary treatment for bacterial infections.

Outcomes from this study highlight for the first time that the secretome from mesenchymal stem cells significantly reduces the formation of bacterial infections, including the antibiotic resistant MRSA, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. Antibiotic resistance has long been a concern and this research highlights some promising new tactics.

###

The full article, The mesenchymal stromal cell (MSC) secretome impairs methicillin-resistant S. aureus (MRSA) biofilms via cysteine protease activity in the equine model, can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0333.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 38th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

Continue reading here:
Study offers potential breakthrough in the war on antibiotic-resistant superbugs - PR Web

Skin Stem Cells Comments Off on Study offers potential breakthrough in the war on antibiotic-resistant superbugs – PR Web | March 30th, 2020

The electronic newsletter I Love My Freedom on a regular basis blasts out e-mails hawking ostentatious rip-offs as well as serpent oil, such as a dementia-reversing miracle therapy, a diabetes destroyer material as well as a life-saving cancer cells treatment that a Nazi drug store allegedly established at Hitlers command. Peppered in between these messages funded by third-party hucksters are main advertisements from Donald Trumps governmental reelection campaign.

For months, participants of the head of states internal circle consisting of Donald Trump Jr., Senate Majority Leader Mitch McConnell (R-Ky), previous House Speaker Newt Gingrich as well as also Trump himself have actually been releasing require contributions with the newsletter, which usually heads out 5 or even more times each day. Many receivers were most likely unintentionally subscribed; I Love My Freedom, the team that runs the eponymous newsletter, has actually obtained an expanding checklist of Americans call info with a concealed e-mail collecting system including an internet of pro-Trump Facebook web pages.

Right- wing political leaders, companies as well as media electrical outlets have a background of dealing with unethical entities behind the scenes to earn money as well as press their programs. The Trump campaigns service with I Love My Freedom is no exemption.

I Love My Freedom (e-mail information multiplied by HuffPost).

By layout, its e-mails seem theyre sent out straight from Trump as well as his allies, though theyre in fact dispersed by means of [emailprotected] At all-time low, they birth please notes noting they were spent for by either the National Republican Senatorial Committee, its House equivalent, the McConnell Senate Committee, or the Trump Make America Great Again Committee (which is collectively run by the Republican National Committee as well as Trumps reelection campaign).

Renting out accessibility to collected e-mail listings is a typical as well as very profitable method worked out by traditional as well as liberal teams alike, commonly for political fundraising objectives. But points obtain morally dirty when e-mail representatives do not veterinarian their enrollers which can lead to e-mail receivers being flooded with ripoffs as well as scams, like the counterfeit cancer cells treatment. In this instance, nonetheless, the genuine inquiry is whether Trumps group troubled to veterinarian I Love My Freedom.

The campaign did not react to HuffPosts ask for remark.

I Love My Freedom, which makes up the newsletter as well as a conservative blog site called Trending Politics, belongs to Making Web LLC, a rare advertising company thats signed up in Minnesota to a 51- year-old male called Allan G. Ferretti.

Through the newsletter alone, I Love My Freedom has actually enhanced a list of aggressive rip-offs consisting of some that misleadingly link Trump, in spite of its negotiations with his campaign. Hours prior to dispersing a fundraising e-mail from the McConnell Senate Committee this month, I Love My Freedom discharged off a funded message advertising a breakthrough stem cell therapy which it baselessly suggested Trump is getting.

This has got Liberals jumping out of their seats, the e-mail checks out. President Trump is in perfect health how is it that hes so seemingly immune to old age? Well in recent years, billionaires like President Trump have increasingly turned to the power of Stem Cells.

Titled Trump Health Bombshell, the e-mail web links to a rambling item pitch that promotes $67 containers of stem cell tablets as the Holy Grail of aging backwards. These tablets make cells inside your body become physically younger, it asserts, without supplying a shred of clinical proof. I Love My Freedom has likewise spammed its customers with enrollers get-rich-quick plans consisting of a secret IRS loophole, as well as has actually routed them to video clips recommending elders ought to exchange their recommended medicines for tricksters supplements also advising that they can pass away if they do not.

Recent newsletter versions have actually circulated actual phony information, as well, installing advertisements camouflaged as write-ups that connect to internet sites stealthily copying genuine media electrical outlets.

I Love My Freedom e-newsletters have actually included misleading advertisements resulting in phony information websites copying genuine electrical outlets..

One such advertisement includes the message Royal Family Mourns As Tragedy Is Confirmed, along with a picture of Meghan Markle, the Duchess ofSussex Clicking on it causes a web site imitating U.S.A. Today that goes crazy regarding a skin care line, which it incorrectly asserts Markle released. Another, birthing the heading [BREAKING NEWS] Prayers Go Out to Oprah Winfrey, web links to a fraudulent information website marketing a Brain Booster supplement, which it brazenly states is in charge of Winfreys occupation success.

In enhancement to Trump, his oldest kid, McConnell as well as Gingrich, I Love My Freedom has actually likewise sent fundraising e-mails in behalf of previous White House press assistant Sarah Huckabee Sanders, House Minority Leader Kevin McCarthy (R-Calif), House Republican Whip Steve Scalise (R-La), previous United Nations Ambassador Nikki Haley,Rep Elise Stefanik (R-N.Y.),Rep David Joyce (R-Ohio), previous White House Deputy Chief of Staff Karl Rove as well as National Republican Congressional Committee Chairman TomEmmer

All were spent for by the NRCC, NRSC, McConnell Senate Committee or the Trump Make America Great AgainCommittee Only the NRCC reacted to an ask for remark.

We rented this list to prospect new donors. We do our best to vet each vendor, but similar to renting a car, it is impossible to know or control what every other renter does with a list they too are renting, spokesperson Chris Pack informed HuffPost.

We will not be using this vendor going forward.

I Love My Freedom constructed its cash-cow e-mail realm by spending virtually $2 million right into Facebook advertisements, which attract individuals in with clickbait surveys or pledges of free MAGA equipment, as well as result in web pages advising them to send their e-mail addresses. This immediately indications them as much as obtain the newsletter, in addition to its numerous funded messages.

The team likewise earns money by marketing Trump- themed product such as Make Liberals Cry Again hats, as well as organizing third-party advertisements on Trending Politics which was seen a million times last month alone, according to electronic analytics device ComparableWeb

I Love My Freedom did not accept HuffPosts ask for a meeting.

I Love My Freedom makes use of clickbait Facebook advertisements to gather individualss e-mails, after that subscribes them to its newsletter.

Ferretti released ilovemyfreedom.org in addition to the Facebook web page Trump for President Fan Club (currently President Donald Trump Fan Club, which has 1.6 million fans) in the summertime of 2015, as reporter April Glaser reported last loss in a write-up regarding I Love My Freedoms viral development on Facebook.

Its among greater than a lots preferred web pages the team runs to run its countless Facebook advertisements, consisting of Donald Trump Is My President, Donald Trump 2020 Voters, President Trump Has My Vote, Donald Trumps Americans, Team Trump Fan Club, The President Trump Fan Club, We Need Trump 2020 as well as President Trumps Patriot Army.

These web pages create a stream of hyper-partisan memes as well as Trending Politics post to their target market of millions. Boosted by Facebooks formula, the advertisements which largely target elders are in some cases seen thousands of countless times each.

This looks like an operation thats got a very highly engaged audience that would be a prime target for a lot of conservative politicians to try to raise grassroots money from, stated Michael Beckel, research study supervisor at the political reform team Issue One.

When you run a pro-Trump Facebook team with greater than a million participants, that can make your [email] checklist an appealing possession.

Trumps campaign has actually currently gathered a citizen e-mail checklist thats so big it leases it out to outdoors celebrations. So why would certainly his group wish to fundraise with I Love My Freedoms checklist particularly provided the teams historical connections to grifters as well as scam artist?

Its type of striking that the Trump campaign is making a financial investment in [I Love My Freedoms] checklist, kept in mindBeckel But a t completion of the day, he stated, much more e-mails still means more potential voters or donors for them.

Calling all HuffPost superfans!

Sign up for subscription to come to be a starting participant as well as aid form HuffPosts following phase

Continued here:
Donald Trump Is Using An Insanely Sketchy Newsletter To Find Campaign Donors - The Union Journal

Skin Stem Cells Comments Off on Donald Trump Is Using An Insanely Sketchy Newsletter To Find Campaign Donors – The Union Journal | March 28th, 2020

LONDON--(BUSINESS WIRE)--The global autologous cell therapy market is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. Request free sample pages

Read the 120-page report with TOC on "Autologous Cell Therapy Market Analysis Report by Therapy (Autologous stem cell therapy and Autologous cellular immunotherapies), Application (Oncology, Musculoskeletal disorders, and Dermatology), Geography (North America, APAC, Europe, South America, and MEA), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/autologous-cell-therapy-market-industry-analysis

The market is driven by the increasing demand for effective drugs for cardiac and degenerative disorders. In addition, the limitations in traditional organ transplantations are fueling the demand for stem cell therapies. All these factors are anticipated to boost the growth of the autologous cell therapy market.

The demand for effective drugs for cardiac and degenerative disorders has been increasing across the world. In addition, the discovery of possible cardiac autologous cells has enabled vendors to develop novel drugs for the treatment of various cardiac diseases. For instance, Mesoblast is developing MPC-150-IM. It is a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Similarly, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a positive impact on the growth of the global autologous cell therapy market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Autologous Cell Therapy Market Companies:

Bayer AG

Bayer AG operates its business through segments such as Pharmaceuticals, Crop Science, Consumer Health, and Animal Health. The company offers induced pluripotent stem cells. They are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. operates its business through an unified business segment. NurOwn is the key offering of the company. It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.

Daiichi Sankyo Co. Ltd.

Daiichi Sankyo Co. Ltd. operates its business through segments such as Innovative Pharmaceuticals, Generic, Vaccine, and OTC Related. Heartcel is the key offering of the company. It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates its business through segments such as Imaging solutions, Healthcare and material solutions, and Document solutions. The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.

Holostem Terapie Avanzate Srl

Holostem Terapie Avanzate Srl operates its business through an unified business segment. Holoclar is the key offering of the company. It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Autologous Cell Therapy Market Therapy Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Application Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Regional Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Cancer Stem Cell Therapeutics Market Global cancer stem cell therapy market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

Global Mantle Cell Lymphoma Therapeutics Market Global mantle cell lymphoma therapeutics market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Original post:
Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Business...

Cardiac Stem Cells Comments Off on Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio – Business… | March 28th, 2020

Researchers at UCL have developed a new way to make blood stem cells present in the umbilical cord 'more transplantable', a finding in mice which could improve the treatment of a wide range of blood diseases in children and adults.

Blood stem cells, also known as haematopoietic stem cells (HSCs), generate every type of cell in the blood (red cells, white cells and platelets), and are responsible for maintaining blood production throughout life.

When treating certain cancers and inherited blood disorders, it is sometimes necessary to replace the bone marrow by allogeneic stem cell transplantation - which involves using stem cells from a healthy donor.

The umbilical cord is a useful source of blood stem cells, and cord blood transplants lead to fewer long-term immune complications than bone marrow transplants. Although umbilical cord transplants have been used in young children for the last 30 years, most cord blood units* contain insufficient HSCs to be suitable for older children and adults and 30% of all units contain too few even for the youngest children, and go to waste.

The study, published in the journal Cell Stem Cell, highlights how a protein called NOV/CCN3, which is normally found at low levels in the blood, can be used to rapidly increase the number HSCs in single umbilical cord blood units that are capable of transplantation. This finding potentially opens the door to units that would otherwise be discarded being made available for patients of all ages.

"Trying to increase the actual number of hematopoietic stem cells in umbilical cord blood is both expensive and challenging. It is known that not all HSCs present in a cord blood unit can or will transplant, indicating that cord blood units have untapped transplantation potential," explained Dr Rajeev Gupta, Clinical Associate Professor at UCL Cancer Institute and first author of the study.

"We explored an alternative approach to harness this potential by increasing the functionality - rather than the number - of HSCs, and so enhance the ability of umbilical cord blood units to transplant.

"We'd previously discovered that a regulatory protein known as NOV is essential for the normal function of human HSCs, and so we asked whether highly purified NOV might be used to manipulate cord blood HSCs to make them more transplantable."

Using cell cultures and mouse models in the lab, the research team at UCL Cancer Institute found that umbilical cord blood units exposed to NOV showed significantly more transplantation potential than regular samples. In fact, the frequency of functional HSCs in the sample increased six-fold. Strikingly, these effects were achieved with only an eight-hour exposure.

"Using NOV, we've shown that we can rapidly manipulate blood stem cells to alter their state - changing non-functioning HSCs to functioning HSCs - which enhances cord blood engraftment potential. This finding offers a new strategy for improving blood transplants. The next stage will be to take our research into a clinical setting to explore how this can benefit patients with blood cancers and other blood disorders," said Dr Gupta.

Commenting on the study, Professor Alejandro Madrigal, Scientific Director of the Anthony Nolan Institute, and a world-leading scientist in the field of stem cell transplantation, said: "Cord blood transplantation has been shown to improve engraftment and provide a better outcome for many people. However, unfortunately, stem cells numbers in many cord blood units might be inadequate for optimal transplantation.

"This research is extremely encouraging, since with the simple addition of NOV/CCN3, there is an increase in the functionality of existing stem cells.

"This practical solution could enable many more cord blood units, which have a limited number of stem cells, to be made available for transplantation and could make a huge difference to the many patients."

Reference:Gupta, R., Turati, V., Brian, D., Thrussel, C., Wilbourn, B., May, G., & Enver, T. (2020). Nov/CCN3 Enhances Cord Blood Engraftment by Rapidly Recruiting Latent Human Stem Cell Activity. Cell Stem Cell. https://doi.org/10.1016/j.stem.2020.02.012

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

*A 'cord blood unit' is one sample of blood retrieved from one umbilical cord.

Read the rest here:
More Effective Stem Cell Transplant Method Could Aid Blood Cancer Patients - Technology Networks

Bone Marrow Stem Cells Comments Off on More Effective Stem Cell Transplant Method Could Aid Blood Cancer Patients – Technology Networks | March 28th, 2020

LONDON--(BUSINESS WIRE)--The global hematopoietic stem cells transplantation (HSCT) market is poised to grow by USD 4.64 billion during 2020-2024, progressing at a CAGR of about 6% during the forecast period. Request free sample pages

Read the 120-page report with TOC on "Hematopoietic Stem Cells Transplantation (HSCT) Market Analysis Report by Type (Autologous HSCT and Allogeneic HSCT), Geographic segmentation (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/hematopoietic-stem-cells-transplantation-market-industry-analysis

The market is driven by the availability of technologically advanced equipment. In addition, the growing demand for personalized medicine is anticipated to boost the growth of the hematopoietic stem cells transplantation (HSCT) market.

The increasing efforts on improving the success rates of HSCT procedure is encouraging the adoption of advanced technologies and sophisticated instruments. For instance, Marrow Cellution, a patented technology, was developed by Ranfac. This technology is gaining traction in the market as it addresses the issues associated with conventional transplant syringe. It prevents contamination of peripheral blood during transplantation. In addition, this technology allows high-quality stem and progenitor cells to harvest within a narrow space. Thus, the availability of technologically advanced equipment is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Hematopoietic Stem Cells Transplantation (HSCT) Market Companies:

AllCells Corp.

AllCells Corp. provides mobilized leukopak, bone marrow and cord blood, whole blood, and leukopak. They also offer Cord Blood, which are collected from a single umbilical cord. They are cryopreserved and offered in the format of isolated cells. Cord Blood products include progenitor cells and CD34 HSCs.

bluebird bio Inc.

bluebird bio Inc. focuses on research, development, and commercialization of potentially transformative gene therapies. The company provides Zynteglo, which is a medicine used to treat patients of 12 years and older who are affected by a blood disorder known as beta thalassaemia.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates under various business segments, namely Imaging solutions, Healthcare and material solutions, and Document solutions. The company offers iCell Hematopoietic Progenitor Cells 2.0.

Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. focuses on research and development of therapeutic products for blood plasma volume expansion, orthopedics, oncology, diagnostic products for the early detection of cancer, neurological diseases and disorders, and more. The company provides OpRegen, which is in Phase I/IIa clinical trial.

Lonza Group Ltd.

Lonza Group Ltd. offers products through the following business segments: Pharma Biotech and Nutrition and Specialty ingredients. The company offers a wide range of stem cells such as bone marrow stromal cells, human peripheral blood CD14+ monocytes, cryopreseverd human CD34+ cells isolated from single donor, osteoclast precusor, and more.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Hematopoietic Stem Cells Transplantation (HSCT) Market Type Outlook (Revenue, USD Billion, 2020-2024)

Hematopoietic Stem Cells Transplantation (HSCT) Market Geographic Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Allogeneic Stem Cells Market Global Allogeneic Stem Cells Market by geography (Asia, Europe, North America, and ROW) and application (regenerative therapy and drug discovery and development).

Cancer Stem Cell Therapeutics Market Global Cancer Stem Cell Therapeutics Market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read more:
Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio...

Bone Marrow Stem Cells Comments Off on Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio… | March 28th, 2020

Mar. 27 /CSRwire/ - As an international non-profit organization, every day DKMS provides 20 lifesaving blood stem cell transplants for blood cancer and blood disorder patients all around the world. Even in the current situation that we are facing with COVID-19, these patients still urgently need our help. It is for this reason that we keep fighting and continue to work together and collaborate with the international blood stem cell community to be able to overcome all barriers, to give as many patients as possible, who are in urgent need of a life-saving blood stem cell transplant, with a second chance at life.

IMPORTANCE OF REGISTRATION

Due to the advice and directions from the health authorities regarding the COVID-19 virus and to play our part to flatten the curve, we have postponed all of our planned donor drives/registration events in all of our six countries. We want to make sure that we look after and protect all of our donors and volunteers. For the thousands of patients around the world who are not able to find a perfect match, we still urgently need to add more donors to the database. We are thankful for every registration and you can still order your registration kit online atwww.dkms.org. Registering is simple and straightforward and you can become a potential lifesaver!

PROTECTING OUR DONORS

Patients around the world still urgently need blood stem cell transplants to survive. This is why we ask all of our donors to make themselves available if they are a match for a patient. The health and well-being of our donors is our number one priority and we consider every case on an individual basis. We will always do everything possible to ensure the safety of our donors.

We have implemented screening for the COVID-19 virus risks before entry to collection centers and before the start of a donation.

These measures serve to protect the donor as well as the recipient and the employees in the collection centers. Health experts have confirmed that there is currently no evidence that the COVID-19 virus can be transmitted via blood, bone marrow, or stem cell products.

We are grateful for every one of our incredible donors and for their commitment to providing patients with a second chance at life.

TRANSPORT OF BLOOD STEM CELL PRODUCTS

75% of all of our life-saving blood stem cell collections from DKMS donors travel across borders to patients in other countries. Due to the travel restrictions imposed by many countries because of the COVID-19 virus, we are faced with additional challenges in ensuring patients receive their transplant.

When it comes to transplants, time is crucial and we are determined to find solutions to be able to provide patients in need with their transplant. We are joining forces with other members of the international transplant community and national and international authorities in order to overcome these challenges. Despite the added difficulties that we are facing at the moment, as always, we are determined to overcome all barriers in order to provide as many patients as possible with a second chance at life.

FAQ's

1. WHY HAVE DONOR DRIVES BEEN CANCELLED OR POSTPONED AND WHAT IS THE ALTERNATIVE?

In light of the increasing spread of the COVID-19 virus, DKMS is postponing all planned events and registration drives for new potential blood stem cell donors until further notice. DKMS sees itself with a special duty of care and with these measures specifically follows the recommendations of the Centers for Disease Control to protect of the population.

Blood cancer patients around the world are still in urgent need of bone marrow and blood stem cell transplants and many are still not able to find a matching donor. This is why DKMS continues to encourage everyone that is able to, to register as a blood stem cell donor and if required, to also make themselves available for a donation."We must not abandon any patient who is currently searching for a blood stem cell donor or waiting for a life-saving blood stem cell transplant. In this difficult situation, I urgently ask that everyone continues to make themselves available as donors. We are taking all precautions necessary to protect each and every one of our donors in the best possible way," said Dr. Elke Neujahr, Global CEO DKMS.

We are grateful for every registration and to enable everyone that is interested to be able to register, DKMS offers the possibility of virtual donor drives that gives initiators, families and friends the opportunity to host a virtual drive to add more potential lifesavers to the donor pool via our online platform which can be found by clicking herehttps://dkmsgetinvolved.org/virtual-donor-drive. With this capability, any planned on ground registration drives can take place digitally instead and potential donors, which are urgently needed, can still register. The links to the online registration drives can be shared via all channels.

As always, registering as a blood stem cell donor via our homepage atwww.dkms.orgis also possible. Anyone who is interested can easily order a registration kit to be sent to their home. With the help of three cotton swabs and clear instructions, as well as a consent form, every potential new donor can take a cheek swab themselves and send it via post back to DKMS. In the DKMS Life Science Lab the individual HLA characteristics (also: tissue characteristics) of the donor are then analyzed, allowing the potential donor to be registered in the DKMS database.

The difference between the online registration drives and the general online registration is that the online registration drives are linked to particular patient appeals and the number of donors can be tracked accordingly. However, in general, it doesnt matter how you register, you will always be available as a potential lifesaver for blood cancer and blood disorder patients searching for a matching donor all over the world!

2. AM I STILL ABLE TO REGISTER ONLINE IF I SUSPECT THAT I MAY HAVE OR DO HAVE COVID- 19?

If it has been confirmed that you have been infected with the COVID-19 virus or you are awaiting test results, you unfortunately will not be able to register until 3 months after the infection has passed.

3. I REGISTERED ONLINE AND HAVENT RECEIVED A CONFIRMATION, IS THERE A DELAY?

We ask anyone registering as a potential donor online for their understanding. Normally we send all registration kits that we receive to our lab within 24 hours, however we are currently waiting 7 days until we do this to ensure the protection of our staff handling the returned registration kits. Please be assured that the analysis of your sample and HLA characteristics that is required for us to add you to the register, will take place as soon as possible.

4. HOW WILL DKMS MAINTAIN THE SAFETY OF DONORS?

The health and safety of our donors is our highest priority. We will consider the circumstances of all of our donors who are asked to donate their bone marrow and blood stem cells, on an individual basis, especially regarding their travel to a collection center. Please be reassured that we provide the best and safest solution possible for our donors.

Unfortunately, donors who live in high risk areas have to be blocked for search requests, as they are currently not eligible to proceed with a donation. We also have implemented screening for the COVID-19 virus risks before entry to any collection center and before the start of a donation. These measures serve to protect the donor as well as the recipient and the employees in the collection centers. Health experts have confirmed that there is currently no evidence that the novel Coronavirus can be transmitted via blood, bone marrow, or stem cell products.

Please also understand that any planned collection may be postponed or cancelled due to the current situation. We will keep you informed about all developments. Regarding the transport of blood stem cell products to the respective transplant clinics, we are in regular and close contact with all parties involved as well as with all relevant national and international authorities and organizations, to ensure that all blood stem cell collections can reach the patients.

5. IS THERE AN INCREASED CHANCE OF DONORS CONTRACTING THE COVID-19 VIRUS DURING THE DONATION PROCEDURE OR PREPARATION FOR THE PR

There is no risk of contracting the COVID-19 virus as a result of a blood stem cell collection. The health and safety of our donors is our number one priority and we will always ensure all procedures are in place to protect their safety.

6. CAN DONORS POSTPONE THEIR DONATION AT THIS TIME?

The final decision to donate is always made by the actual donor. If you have been asked to donate and have any concerns, please contact your DKMS coordinator. We evaluate each case on an individual basis to find the best solution for all parties involved.

7. IS IT STILL SAFE FOR PATIENTS TO RECEIVE A TRANSPLANT?

Health experts have confirmed that there is currently no evidence that the novel Coronavirus can be transmitted via blood, bone marrow, or stem cell products.

8. HOW IS THE TRANSPORT OF COLLECTIONS FROM DONORS IMPACTED BY THE CURRENT TRAVEL RESTRICTIONS?

The majority of blood stem cell collections from DKMS donors travel across borders to patients in other countries. Due to the travel restrictions imposed by many countries we are in regular and close contact with all parties involved in the transport, as well as with the relevant national and international authorities and organizations. Despite the added difficulties that we are facing at the moment, we are, as always, determined to overcome all barriers in order to provide as many patients as possible with a second chance at life.

9. HOW IS DKMS RESPONDING TO THE CURRENT TRAVEL RESTRICTIONS IN THE US?

Due to the restrictions on entry into the USA, DKMS has been in contact with the World Marrow Donor Association (WMDA) and the National Marrow Donor Program (NMDP). Together, we obtained special permits for stem cell couriers from Germany and Europe to enter the USA.

10. HOW WILL THE SPREAD OF THE COVID-19 VIRUS AFFECT DKMS AND ITS OPERATIONS?

As with every organization across the world, DKMS faces challenges caused by COVID-19 and some of the potential impacts are still not yet known. The goal of DKMS remains the same as it always has been and that is, together with our outstanding team of donors and employees, to give as many patients as possible around the world a second chance at life, through a life-saving bone marrow and blood stem cell transplant. The management team of DKMS is working around the clock together with all DKMS employees and relevant stakeholders to achieve this goal.

11. HOW WILL DKMS RESPOND AS THE SITUATION EVOLVES?

A dedicated team made up of experts from relevant departments at DKMS is constantly monitoring and evaluating the ongoing situation and will act accordingly. We will continue to keep our donors and all stakeholders updated.

12. IS DKMS TESTING POTENTIAL DONORS DURING THE REGISTRATION PROCESS?

DKMS does not test potential donors who register with us for the COVID-19 virus. If you are confirmed to have the virus, we ask that you do not register with us for the next 3 months. For donors who are asked to donate we have implemented screening for the COVID-19 virus risks before entering any collection center and before the start of a donation. These measures serve to protect the donor as well as the recipient and the employees in the collection center.

13. IF I AM A POTENTIAL DONOR AND I HAVE QUESTIONS, WHO SHOULD I CONTACT?

If you have been contacted by DKMS as a potential donor and if you have any questions or concerns, you are encourage to contact your DKMS coordinator. As always, DKMS staff is there to help you through the process and answer any questions that you may have.

14. IS THERE A NEED FOR QUARANTINE OR TESTING OF STEM CELL PRODUCTS BEFORE TRANSPLANTATION?

Although SARS-CoV and MERS-CoV have been detected in blood, there have not been any reports of transmission from donor to recipient either in transfusion of blood products or cellular therapies. As there is no evidence of transmission via blood, bone marrow, or stem cell products DKMS endorses the recommendations of the regulatory agencies such as the FDA and AABB which currently do not recommend or require product testing or to quarantine the stem cell product. For more information, please visit:share.wmda.info.

If a patient is in need of a transplant, there is no need to wait or prolong the process by testing or quarantining the stem cell product. Planned transplantations can go ahead.

See more here:
Now More Than Ever, the Importance of Second Chances at Life - CSRwire.com

Bone Marrow Stem Cells Comments Off on Now More Than Ever, the Importance of Second Chances at Life – CSRwire.com | March 28th, 2020

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Viewpoint

Decorated with a team of 300+ analysts, Hematopoietic Stem Cell Transplantation (HSCT) Market Report serves each and every requirement of the clients while preparing market reports. With digital intelligence solutions, we offer actionable insights to our customers that help them in overcoming market challenges. Our dedicated team of professionals perform an extensive survey for gathering accurate information associated with the market.

Hematopoietic Stem Cell Transplantation (HSCT) Market Research, in its latest business report elaborates the current situation of the global Hematopoietic Stem Cell Transplantation (HSCT) market in terms of volume (x units), value (Mn/Bn USD), production, and consumption. The report scrutinizes the market into various segments, end uses, regions and players on the basis of demand pattern, and future prospect.

In this Hematopoietic Stem Cell Transplantation (HSCT) market study, the following years are considered to project the market footprint:

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2542619&source=atm

The following manufacturers are covered:Escape Therapeutics Inc.Cryo-Save AGRegen Biopharma Inc.CBR Systems Inc.ViaCord Inc.Lonza Group Ltd.Pluristem Therapeutics Inc.China Cord Blood Corp.

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAllogeneicAutologous

Segment by ApplicationPeripheral Blood Stem Cells Transplant (PBSCT)Bone Marrow Transplant (BMT)Cord Blood Transplant (CBT)

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2542619&source=atm

The Hematopoietic Stem Cell Transplantation (HSCT) market research addresses the following queries:

After reading the Hematopoietic Stem Cell Transplantation (HSCT) market report, readers can

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2542619&licType=S&source=atm

The market study depicts an extensive analysis of all the players running in the Hematopoietic Stem Cell Transplantation (HSCT) market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies, and mergers & acquisitions associated with the players are enclosed in the Hematopoietic Stem Cell Transplantation (HSCT) market report.

For More Information Kindly Contact:

marketresearchhub.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Visit link:
Hematopoietic Stem Cell Transplantation (HSCT) Market Projected to Experience Major Revenue Boost During the Period Between 2019-2048 - Daily Science

Bone Marrow Stem Cells Comments Off on Hematopoietic Stem Cell Transplantation (HSCT) Market Projected to Experience Major Revenue Boost During the Period Between 2019-2048 – Daily Science | March 28th, 2020

The Global Stem Cells Market is expected to grow from USD 115.46 Million in 2018 to USD 325.84 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 15.97%.

The global Stem Cells market research report is a professional research report and in-depth study on the current state on the Stem Cells practices market industry.

The research report presents global drivers, restraints, opportunities trends and forecasts up to 2025. The report further indicates the positive aspects of the industry that influence market growth and trends.

Some of the prominent players operating in this market include: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Stem Cells Market including are Anterogen Co., Ltd., Holostem Terapie Avanzate Srl, Medipost Co., Ltd., Osiris Therapeutics, Inc., Pharmicell Co., Ltd., Allosource, JCR Pharmaceuticals Co., Ltd., Nuvasive, Inc., and RTI Surgical, Inc.. On the basis of Cell Source, the Global Stem Cells Market is studied across Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, and Cord Blood/Embryonic Stem Cells.On the basis of Type, the Global Stem Cells Market is studied across Allogeneic Stem Cell Therapy and Autologous.On the basis of Therapeutic Application , the Global Stem Cells Market is studied across Cardiovascular Diseases, Gastrointestinal Diseases, Musculoskeletal Disorders, Surgeries, and Wounds and Injuries.

________________________________________________________________________________

Request a sample of this market study: https://www.regalintelligence.com/request-sample/23796

________________________________________________________________________________

The report overviews the industry including definitions and classifications. The Stem Cells Market report provides international markets including development trends, competitive landscape analysis and key development regions. Market strategies and development policies are briefly discussed. Furthermore, manufacturing process, cost, price and revenue are deeply analysed with a reflection to import/export consumption, supply and demand, and national & international gross-margins.

The objective of Studies:

________________________________________________________________________________

Ask For [emailprotected] https://www.regalintelligence.com/check-discount/23796

________________________________________________________________________________

The Stem Cells industry is lucrative due to the presence of several small and large market players. Market strategies adopted by manufactures for increasing the sales in the market have been presented. The data and manufacturers are evaluated on the basis of basic information, manufacturing information, and competitors. The recent developments that took place in the global Stem Cells market and their impact on the future growth of the market have also been presented in the industry.

Reasons to Buy this Report:

Table of Content:

________________________________________________________________________________

Ask For Table of [emailprotected] https://www.regalintelligence.com/request-toc/23796

________________________________________________________________________________

Thank you for visiting this article.

See the original post:
Players Expected to Witness Maximum Growth | Stem Cells Market - Monroe Scoop

Bone Marrow Stem Cells Comments Off on Players Expected to Witness Maximum Growth | Stem Cells Market – Monroe Scoop | March 28th, 2020

In the past, an injury to the stifle joint of a horse may have certainly ended his or her career or usefulness. Now, with the ever-evolving science of veterinary medicine, afflictions to the joint have a much higher chance of being treated or even healed.

One of the reasons a stifle injury gives apprehension to horse owners is the complicated nature of the joint said Scott Cammack, D.V.M. He practices at Northern Hills Veterinary Clinic in Sturgis, South Dakota, with several other specialists.

Cammack explains that its treatment is much more involved than similar injuries. For example, an injury to the hock can often be resolved by fusing the bottom two joints (the hock consists of four total). Because it is a low-motion joint, the horse will still be sound and function after fusion.

The stifle, on the other hand, is a high-motion joint. Its got a lot of things going on in there. It doesnt have the capacity to be fused and still be sound. I would consider that they are more serious. They are more prone to long-term issues than a hock is, in my mind, he said.

According to Dr. Cammack, the stifle is anatomically similar to a human knee. All the parts are similar to your knee. Just as athletes injure their knees, they injure themselves. They have a patella, theyve got meniscuses, theyve got anterior and posterior cruciate ligaments, theyve got collateral ligaments. One major difference is that humans have one patellar ligament coming off the kneecap, while horses have three. Therefore, horses can have very unique issues.

One condition, often found in younger horses (aged 2-6) is the intermittent upward fixation of the patella or simply a catchy stifle. Dr. Cammack describes this condition: The locking mechanism of the stifle is inappropriately keeping the leg in the locked, extended position. They cant bend their leg and it only bends at the fetlock. That one is one that we treat in different ways. Sometimes, well do a procedure where we put a needle in the medial patellar ligament and we split it a little bit and cause it to thicken up and tighten up a little bit to help correct that. So thats a pretty simple procedure.

Another condition found in younger horses is OCD (osteochondrosis) lesions, a developmental issue. According to Dr. Cammack, they are cyst-like lesions on the bone. Some of them fill in and some require surgery. We saw one just the other day. A four year old had large cysts up in the bone. All they did was turn the horse out and waited. That one filled in on its own, but thats not common. Usually youre injecting the cyst or putting a screw across it or various treatments for something like that.

On the other hand, older horses may have very different afflictions in the joint. He said, In my mind, youre going to see more of the soft tissue injuries in your younger horses and more of the osteoarthritis in the older horses.

Older horses are going to be more prone to seeing arthritis in their stifle, which might be secondary to an injury it had had way back when. They injured a collateral ligament and it wasnt diagnosed, or they have some instability from ligament damage and then it healed some and they got by with it. Years down the road, youre seeing the arthritis, the osteoarthritis in there.

Stifle injuries are often seen in performance horses in various disciplines. When you start getting into any disciplines where theyre having to run hard, turn hard, stop hard, spin. We see it more in the reined cow horses and the reiners and the barrel horses, Dr. Cammack said. However, injuries can occur on the ranch or in other disciplines, as well. Certainly any horse can catch some bad ground or find a hole in the ground or something that can cause them injury.

Interestingly, younger horses may be more prone to injuries that occur in the arena. We are doing our futurities and so much heavy training on them when theyre young and they dont have the muscle memory and the skillset to have their leg in the right place at the right time with that amount of force on it.

Dr. Cammacks procedure for examining horses includes a flex test, where the joint is stressed momentarily to determine the location of any potential weaknesses in the joints. The end goal is to determine how to optimize the horses performance without masking any problems. If the horse deals with chronic issues, the typical injection of HA (hyaluronic acid), a type of steroid, may be administered, costing around $175.

For other injuries, different types of injections may do the trick. Theres certainly a lot more going on with regenerative medicine than there used to be, Dr. Cammack said. Using PRP (platelet-rich plasma) can help the joint heal itself. Youre taking the blood and processing it and pulling out platelet-rich plasma. Its going to have healing factors and certain proteins that can help the joint get better. This may cost around $250.

Theres another one called pro-stride, which is another form of PRP, but its a more concentrated form of PRP. Its more like $450. If youre getting into stem cells, that goes right up. We just pull the bone marrow or the fat, depending on which form were doing and we send it in. With that sample that we send in, we have to send $2,300 to the laboratory. That one can be in excess of $2,500 to do stem cells, Dr. Cammack said. Its an exciting area.

Cammack has devoted his professional career to the study of equines and particularly their joints and movement.

When I was in college, I started working at this clinic with Dr. Margie Jones. I developed a strong affinity for equine work and did a year internship with an equine surgeon in California, but he did a sports medicine practice and then I got in the deep pool of sports medicine and developed a deep love for it, he said.

More severe injuries to the stifle may involve surgeries, which range vastly in involvement and price.

This article serves as a brief overview of a very large field of veterinary study. Dr. Cammack devotes much of his practice and time to learning more about the equine, attending the yearly American Association of Equine Practitioners conferences, and expanding into regenerative medicine.

Read the rest here:
Stifle injuries and treatments - Tri-State Livestock News

Bone Marrow Stem Cells Comments Off on Stifle injuries and treatments – Tri-State Livestock News | March 28th, 2020